MCID: CRB138
MIFTS: 41

Core Binding Factor Acute Myeloid Leukemia malady

Category: Cancer diseases

Aliases & Classifications for Core Binding Factor Acute Myeloid Leukemia

About this section

Aliases & Descriptions for Core Binding Factor Acute Myeloid Leukemia:

Name: Core Binding Factor Acute Myeloid Leukemia 24 66
Cbf Acute Myeloid Leukemia 24
 
Core-Binding Factor Aml 24
Cbf-Aml 24

Classifications:



Summaries for Core Binding Factor Acute Myeloid Leukemia

About this section
Genetics Home Reference:24 Core binding factor acute myeloid leukemia (CBF-AML) is one form of a cancer of the blood-forming tissue (bone marrow) called acute myeloid leukemia. In normal bone marrow, early blood cells called hematopoietic stem cells develop into several types of blood cells: white blood cells (leukocytes) that protect the body from infection, red blood cells (erythrocytes) that carry oxygen, and platelets (thrombocytes) that are involved in blood clotting. In acute myeloid leukemia, the bone marrow makes large numbers of abnormal, immature white blood cells called myeloid blasts. Instead of developing into normal white blood cells, the myeloid blasts develop into cancerous leukemia cells. The large number of abnormal cells in the bone marrow interferes with the production of functional white blood cells, red blood cells, and platelets.

MalaCards based summary: Core Binding Factor Acute Myeloid Leukemia, also known as cbf acute myeloid leukemia, is related to leukemia and myeloid leukemia. An important gene associated with Core Binding Factor Acute Myeloid Leukemia is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways are Thyroid cancer and MNAR-PELP1 and Estrogen Receptor Interaction. Affiliated tissues include myeloid, bone and bone marrow, and related mouse phenotypes are respiratory system and neoplasm.

Related Diseases for Core Binding Factor Acute Myeloid Leukemia

About this section

Diseases related to Core Binding Factor Acute Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 70)
idRelated DiseaseScoreTop Affiliating Genes
1leukemia10.9
2myeloid leukemia10.9
3acute myeloid leukemia, somatic dnmt3a-related10.7FLT3, KIT
4acute panmyelosis with myelofibrosis10.7FLT3, KIT
5vagina sarcoma10.7HRAS, KRAS
6glomerulosclerosis10.6HRAS, KRAS
7gonococcal spondylitis10.6HRAS, KRAS
8aml with myelodysplasia-related features10.6CBFB, FLT3, KIT
9pterygium colli mental retardation digital anomalies10.5KRAS, NRAS
10myxosarcoma10.5HRAS, KRAS
11unclassified intestinal pseudoobstruction10.5FLT3, KIT, RUNX1
12brachydactyly, type e210.5KRAS, NRAS
13melanocytic nevus syndrome, congenital, somatic10.5HRAS, NRAS
14rad51c-related fanconi anemia10.5KRAS, NRAS
15seminal vesicle chronic gonorrhea10.5HRAS, KRAS
16alg12-congenital disorder of glycosylation10.5FLT3, KIT, RUNX1
17demyelinating polyneuropathy10.5HRAS, NRAS
18breast papillary carcinoma10.5HRAS, KIT, KRAS
19leukemoid reaction10.5KIT, NRAS
20ureter adenocarcinoma10.5HRAS, KRAS
21vibratory urticaria10.5HRAS, KIT, KRAS
22lateral medullary syndrome10.5KIT, NRAS
23coloboma of macula and skeletal anomalies10.5HRAS, NRAS
24psammomatous meningioma10.4HRAS, NRAS
25hypervitaminosis a10.4CSF1R, KIT
26gastrointestinal neuroendocrine tumor10.4HRAS, KIT, KRAS
27thrombocythemia 310.4FLT3, JAK2, KIT
28trachea adenoid cystic carcinoma10.4HRAS, KRAS
29chronic inflammatory demyelinating polyradiculoneuropathy10.4HRAS, NRAS
30gallbladder papillomatosis10.4HRAS, KIT, KRAS
31hypersplenism10.4KIT, NRAS
32spindle epithelial tumor with thymus-like differentiation tumor10.4HRAS, KRAS
33mastroiacovo de rosa satta syndrome10.4JAK2, KIT, NRAS
34sublingual gland adenoid cystic carcinoma10.4HRAS, KIT, NRAS
35tonsillar pillar cancer10.4FLT3, KIT
36vulvar sarcoma10.4HRAS, KIT, NRAS
37epidermal nevus, somatic10.3HRAS, KRAS, NRAS
38melanoma10.3HRAS, KIT, NRAS
39schimmelpenning-feuerstein-mims syndrome, somatic mosaic10.3HRAS, KRAS, NRAS
40esophagus leiomyosarcoma10.3HRAS, KIT, NRAS
41uterine ligament serous adenocarcinoma10.3HRAS, KRAS
42adenofibroma10.3HRAS, KRAS, NRAS
43dermatosis papulosa nigra10.3HRAS, KRAS, NRAS
44heavy chain disease10.3HRAS, KIT, NRAS
45dubin-johnson syndrome10.3HRAS, KIT, NRAS
46leopard syndrome 110.3HRAS, KRAS, NRAS
47atrial standstill10.3HRAS, KRAS, NRAS
48appendix mucinous cystadenocarcinoma10.3HRAS, KRAS
49pilocytic astrocytoma of cerebellum10.3HRAS, KRAS, NRAS
50neonatal stroke10.2CBL, HRAS, NRAS

Graphical network of the top 20 diseases related to Core Binding Factor Acute Myeloid Leukemia:



Diseases related to core binding factor acute myeloid leukemia

Symptoms for Core Binding Factor Acute Myeloid Leukemia

About this section

Drugs & Therapeutics for Core Binding Factor Acute Myeloid Leukemia

About this section

Drugs for Core Binding Factor Acute Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
CytarabinePhase 3, Phase 1, Phase 21074147-94-46253
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
(beta-D-arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
1-Arabinofuranosylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta -D-Arabinofuranosylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta-D-Arabinofuranosyl-Cytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1-beta-D-Arabinosyl-Cytosine
1-beta-D-Arabinosylcytosine
147-94-4
1beta -Arabinofuranasylcytosine
1beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1beta-D-Arabinofuranosylcytosine
1beta-D-Arabinosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
AR3
Alexan
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Ara-Cytidine
AraC
Arabinocytidine
Arabinofuranosyl Cytidine
Arabinofuranosylcytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
Aracytidine
Aracytin
Aracytine
Arafcyt
BIDD:GT0371
BIDD:PXR0139
BTB15125
Beta-cytosine arabinoside
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
CPD000449317
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Citarabina
Citarabina [INN-Spanish]
Cytarabin
Cytarabina
Cytarabine
Cytarabine (JP15/USP/INN)
 
Cytarabine [USAN:INN:BAN:JAN]
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-beta -D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta-D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosinearabinoside
D00168
DB00987
DepoCyte
Depocyt
Depocyt (TN)
Depocyt (liposomal)
Depocyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
LS-860
Lopac0_000316
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
SR-01000075773-3
Spongocytidine
TL8001048
Tarabine
U 19920A
U-19,920
U-19920
UNII-04079A1RDZ
Udicil
ZINC03795098
beta -D-arabinosylcytosine
beta -arabinosylcytosine
beta -cytosine arabinoside
beta-Ara C
beta-Ara c
beta-Arabinosylcytosine
beta-Cytosine arabinoside
beta-D-Arabinosylcytosine
cytarabine
cytarabine liposome injection
cytosine-β-D-arabinofuranoside
2
DaunorubicinPhase 3, Phase 1, Phase 225920830-81-330323
Synonyms:
(+)-Daunomycin
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
11006-54-5
11048-29-6
1407-15-4
149541-57-1
20830-81-3
23942-76-9
27576-81-4
28020-80-6
AB00514669
AC1L1JCP
AC1Q29OI
AI3-52942
Acetyladriamycin
Anthracyline
Antibiotics From Streptomyces Coeruleorubidus
Antibiotics from Streptomyces coeruleorubidus
BPBio1_000389
BRD-K43389675-003-02-7
BRN 1445583
BSPBio_000353
C01907
CCRIS 914
CHEBI:41977
CHEMBL178
CID30323
Cerubidin
Cerubidine
D07776
DAUNORUBICIN HCL
DB00694
DM1
Daunamycin
Daunarubicinum
Dauno-Rubidomycine
DaunoXome
DaunoXome (TN)
Daunoblastin
Daunoblastine
Daunomycin
 
Daunomycin Hydrochloride
Daunomycin, Hydrochloride
Daunorrubicina
Daunorubicin
Daunorubicin (INN)
Daunorubicin (liposomal)
Daunorubicin Hcl
Daunorubicin Hydrochloride
Daunorubicin [INN:BAN]
Daunorubicin, Hydrochloride
Daunorubicina
Daunorubicine
Daunorubicinum
Daunorubicinum [INN-Latin]
Daunoxome
EINECS 244-069-7
FI 6339
FI6339
HMS2089H04
HMS2091K06
HSDB 5095
LMPK13050002
LS-187381
LS-997
Leukaemomycin C
MolPort-002-533-961
NCGC00024246-05
NCGC00024246-06
NCGC00025173-01
NCI-C04693
NChemBio.2007.10-comp14
NSC 83142
NSC-82151
Ondena
Prestwick3_000487
RCRA waste no. U059
RP 13057
Rcra Waste No. U059
Rp 13057 Hydrochloride
Rubidomycin
Rubidomycin Hydrochloride
Rubomycin
Rubomycin C
Tocris-1467
UNII-ZS7284E0ZP
VS-103
daunorubicin
nchembio723-comp2
3
DasatinibPhase 3, Phase 2, Phase 1276302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
Dasatinibum
EC-000.2122
 
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
anh. dasatinib
dasatinib
dasatinib (anhydrous)
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
4
MitoxantronePhase 226465271-80-94212
Synonyms:
1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE
1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione
1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione
1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon
1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione
137635-96-2
2fum
5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone
65271-80-9
70476-82-3
70476-82-3 (hydrochloride)
70711-41-0
70711-41-0 (acetate)
70945-62-9
9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9CI)
AB00053716
AC1L1HNY
AN-584/42007670
BIDD:PXR0181
BPBio1_000627
BRD-K21680192-300-05-2
BRD-K21680192-300-07-8
BRN 2795126
BSPBio_000569
BSPBio_003160
C11195
C22H28N4O6
CAS-70476-82-3
CCRIS 7604
CHEBI:50729
CHEMBL58
CID4212
D08224
DB01204
DHAD
DHAQ
DHAQ (*Diacetate salt*)
DHAQ HCl
Dihydroxyanthraquinone
DivK1c_000516
HMS2090D05
IDI1_000516
KBio1_000516
KBio2_002135
KBio2_004703
KBio2_007271
KBio3_002660
KBioGR_001531
KBioSS_002135
LS-20638
Liposome Encapsulated Mitoxantrone (LEM)
Lopac-M-6545
Lopac0_000779
MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE
MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE
MIX
 
MLS002703044
Misostol
Misostol (TN)
Mitox
Mitoxanthrone
Mitoxantron
Mitoxantrona
Mitoxantrona [INN-Spanish]
Mitoxantrone
Mitoxantrone (INN)
Mitoxantrone (free base)
Mitoxantrone 2HCl
Mitoxantrone HCl
Mitoxantrone [INN]
Mitoxantrone dihydrochloride
Mitoxantrone hydrochloride
Mitoxantronum
Mitoxantronum [INN-Latin]
Mitozantrone
Mitozantrone hydrochloride
MolPort-003-849-239
NCGC00015693-01
NCGC00015693-02
NCGC00015693-04
NCGC00162251-01
NCI60_002276
NCI60_002535
NChemBio.2007.10-comp17
NINDS_000516
NSC 279836
NSC-279836
NSC-287836
NSC-299195
NSC-301739
NSC-301739D
NSC279836
NSC299195
NSC301739
Neuro_000153
Novantron
Novantrone
Novantrone(R) (mitoxantrone for injection concentrate)
Prestwick0_000385
Prestwick1_000385
Prestwick2_000385
Prestwick3_000385
S2485_Selleck
SMP2_000179
SMR001549953
SPBio_000756
SPBio_002490
SR-01000076001
SR-01000076001-7
STK631833
Spectrum2_000908
Spectrum3_001590
Spectrum4_000866
Spectrum5_001205
Spectrum_001655
UNII-BZ114NVM5P
VU0244399-2
mitoxantrone
5
alvocidibPhase 259131740-09-55287969
Synonyms:
(-)cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one
131740-09-5
146426-40-6
1c8k
1e1y
2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one
358739-39-6
AC1NRALK
Alvocidib
Alvocidib [INN]
C21H20ClNO5
CHEMBL428690
CHEMBL8817
CID5287969
 
DB03496
FLAVO
Flavopiridol
Flavopiridol hydrochloride
HMR-1275
HMR-1275, Alvocidib, L868275, Flavopiridol
L 868275
L-868275
L86-8275
L868275
LS-173272
NSC649890
S1230_Selleck
UNII-45AD6X575G
alvocidib
flavopiridol
6
IdarubicinPhase 2, Phase 121158957-92-942890
Synonyms:
(1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-|A-l-lyxo-hexopyranoside
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione
4-DMD
4-Demethoxydaunomycin
4-Demethoxydaunorubicin
4-Desmethoxydaunorubicin
57852-57-0
57852-57-0 (HYDROCHLORIDE)
58957-92-9
AC1L28SA
AC1Q6JJ4
BRD-K69650333-001-01-1
C26H27NO9
CCRIS 5083
CHEBI:42068
CHEMBL1117
CID42890
D08062
DB01177
DM5
DMDR
EU-0100600
HMS2089D05
I 1656
I06-1097
I1656_SIGMA
IDARUBICIN
 
IMI 30
IMI-30
Idamycin
Idamycin PFS
Idarubicin (INN)
Idarubicin Aglycone
Idarubicin HCl PFS
Idarubicin Hcl
Idarubicin Hcl Pfs
Idarubicin Hydrochloride
Idarubicin [INN:BAN]
Idarubicina
Idarubicina [INN-Spanish]
Idarubicine
Idarubicine [INN-French]
Idarubicinum
Idarubicinum [INN-Latin]
KBioSS_002388
LS-94015
Lopac0_000600
MLS000759470
NCGC00093976-01
NCGC00093976-02
NCGC00093976-03
NCGC00093976-04
NSC-256439
NSC256439
SMR000466355
UNII-ZRP63D75JW
Zavedos
Zavedos (TN)
idarubicin hydrochloride
7
VidarabinePhase 2, Phase 147524356-66-932326, 21704
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9-Arabinosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
ADENOSINE, U.S.P.
ADN
AI3-52413
AI3-52821
AR-1H6029
ARA-A NSC 247519
Ade-Rib
Adenine Arabinoside
Adenine arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
Adenosine-8-14C
Adensoine
Ambap5536-17-4
Ara A
Ara-A
Ara-ATP
Araadenosine
Arabinoside Adenine
Arabinoside adenine
Arabinosyl Adenine
Arabinosyl adenine
Arabinosyl-adenine
Arabinosyladenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
Bio1_000437
Bio1_000926
Bio1_001415
Boniton
C00212
CAS-5536-17-4
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
Caswell No. 010B
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
 
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
LS-15059
LS-15085
Lopac0_000123
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC-404241
NSC247519
NSC404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
PDSP1_001036
PDSP2_001020
Pallacor
Polyadenosine
Polyriboadenosine
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
Prestwick_983
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
SPECTRUM1500107
SPECTRUM1500609
SR 96225
SR-96225
STK361815
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spectrum_001894
Spongoadenosine
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
VIRDARABINE
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira ATM
Vira-A
Vira-A, Vidarabine
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
adenine-D-ribose
adenosine
alpha-Ara A
beta-Adenosine
beta-Ara A
beta-D-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
8
FludarabinePhase 2, Phase 1109221679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ARAA
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-fluoro ARA-A
21679-14-1
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
Fludara, Fludarabine
 
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
9
BusulfanPhase 253255-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
10
EtoposidePhase 2121033419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
 
Eposin, Vepesid, VP-16, Toposar, Etoposide
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
11lenograstimPhase 21178

Interventional clinical trials:

(show all 12)
idNameStatusNCT IDPhase
1Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AMLRecruitingNCT02926586Phase 4
2Timed-Sequential Induction in CBF-AMLCompletedNCT00428558Phase 3
3Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)RecruitingNCT02013648Phase 3
4Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous LeukemiaCompletedNCT02113319Phase 2
5Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)CompletedNCT00850382Phase 1, Phase 2
6Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00407966Phase 2
7Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid LeukemiaRecruitingNCT01050036Phase 2
8Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)RecruitingNCT01146977Phase 2
9Fludarabine, Cytarabine, Filgrastim and Idarubicin in Core Binding Factor (CBF) LeukemiasRecruitingNCT00801489Phase 2
10Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT01238211Phase 2
11Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid LeukemiaRecruitingNCT02680951Phase 1
12Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid LeukemiaRecruitingNCT01066286

Search NIH Clinical Center for Core Binding Factor Acute Myeloid Leukemia

Genetic Tests for Core Binding Factor Acute Myeloid Leukemia

About this section

Anatomical Context for Core Binding Factor Acute Myeloid Leukemia

About this section

MalaCards organs/tissues related to Core Binding Factor Acute Myeloid Leukemia:

34
Myeloid, Bone, Bone marrow, Eye

Animal Models for Core Binding Factor Acute Myeloid Leukemia or affiliated genes

About this section

MGI Mouse Phenotypes related to Core Binding Factor Acute Myeloid Leukemia:

39 (show all 20)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053888.8CBFB, CBL, HRAS, KIT, KRAS, RUNX1
2MP:00020068.6CBFB, FLT3, HRAS, JAK2, KIT, KRAS
3MP:00053828.4CBFB, CBL, CSF1R, HRAS, KIT, KRAS
4MP:00053718.3CBFB, CBL, CSF1R, KIT, KRAS, NRAS
5MP:00053858.2CBFB, CBL, HRAS, KIT, KRAS, NRAS
6MP:00053708.0ABCG2, CBFB, CBL, JAK2, KIT, KRAS
7MP:00030127.6ABCG2, CBFB, CSF1R, FLT3, HRAS, KIT
8MP:00053907.5CBFB, CBL, CSF1R, FLT3, HRAS, JAK2
9MP:00107687.3CBFB, CBL, CSF1R, FLT3, HRAS, JAK2
10MP:00053797.2CBFB, CBL, CSF1R, FLT3, HRAS, JAK2
11MP:00053847.2ABCG2, CBFB, CBL, CSF1R, FLT3, JAK2
12MP:00028737.2ABCG2, CBFB, CSF1R, HRAS, JAK2, KIT
13MP:00053787.2CBFB, CBL, CSF1R, FLT3, HRAS, JAK2
14MP:00053766.6ABCG2, CBFB, CBL, CSF1R, FLT3, HRAS
15MP:00107716.4ABCG2, CBFB, CBL, CSF1R, CSF3, HRAS
16MP:00053876.4ABCG2, CBFB, CBL, CSF1R, CSF3, FLT3
17MP:00053976.3ABCG2, CBFB, CBL, CSF1R, CSF3, FLT3

Publications for Core Binding Factor Acute Myeloid Leukemia

About this section

Articles related to Core Binding Factor Acute Myeloid Leukemia:

(show top 50)    (show all 56)
idTitleAuthorsYear
1
Prognostic importance of c-kit mutations in core binding factor acute myeloid leukemia: A systematic review. (27613372)
2016
2
Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia. (26880987)
2016
3
Comprehensive mutational profiling of core binding factor acute myeloid leukemia. (26980726)
2016
4
Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. (26771376)
2016
5
Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis. (27597292)
2016
6
Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. (27298396)
2016
7
Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia. (26771813)
2016
8
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission. A French Acute Myeloid leukemia Intergroup trial. (25715404)
2015
9
Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population. (25932436)
2015
10
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. (25753065)
2015
11
Additional chromosomal abnormalities in core-binding factor acute myeloid leukemia. (26681050)
2015
12
Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities. (26111469)
2015
13
High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML). (24844781)
2014
14
Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. (25348871)
2014
15
Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. (24793731)
2014
16
Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy. (25088818)
2014
17
Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center. (25449688)
2014
18
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. (23053179)
2013
19
Prognosis of patients with core binding factor acute myeloid leukemia after first relapse. (23716553)
2013
20
Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease. (23646898)
2013
21
Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. (24226631)
2013
22
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. (23783394)
2013
23
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. (23321257)
2013
24
Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. (23677335)
2013
25
Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? (24319183)
2013
26
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. (23266036)
2013
27
Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia. (22145956)
2012
28
High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. (22234698)
2012
29
Impact of residual normal metaphases in core binding factor acute myeloid leukemia. (21928314)
2012
30
A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia. (22886749)
2012
31
Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. (21715005)
2011
32
Treatment strategies in patients with core-binding factor acute myeloid leukemia. (21755276)
2011
33
Core binding factor acute myeloid leukemia (CBF-AML) in MAcxico: a single institution experience. (21574542)
2011
34
Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye. (20709669)
2010
35
Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. (19126873)
2009
36
Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? (19468270)
2009
37
Rapid detection of KIT mutations in core-binding factor acute myeloid leukemia using high-resolution melting analysis. (19644024)
2009
38
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. (18981008)
2008
39
Core binding factor acute myeloid leukemia. (18692691)
2008
40
Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. (17960171)
2008
41
A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. (18297529)
2008
42
Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia. (18940681)
2008
43
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. (18841055)
2008
44
Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. (17485551)
2007
45
Core binding factor acute myeloid leukemia. (16728942)
2006
46
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). (16598313)
2006
47
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. (16015387)
2005
48
Expression of the neural cell adhesion molecule CD56 is not associated with P-glycoprotein overexpression in core-binding factor acute myeloid leukemia. (15068897)
2004
49
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. (15289486)
2004
50
Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. (14695213)
2003

Variations for Core Binding Factor Acute Myeloid Leukemia

About this section

Expression for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

About this section
Search GEO for disease gene expression data for Core Binding Factor Acute Myeloid Leukemia.

Pathways for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

About this section

Pathways related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show top 50)    (show all 86)
idSuper pathwaysScoreTop Affiliating Genes
19.5HRAS, KRAS, NRAS
29.5HRAS, KRAS, NRAS
39.5HRAS, KRAS, NRAS
49.5HRAS, KRAS, NRAS
59.5HRAS, KRAS, NRAS
69.5HRAS, KRAS, NRAS
79.5HRAS, KRAS, NRAS
89.5HRAS, KRAS, NRAS
99.5HRAS, KRAS, NRAS
10
Show member pathways
9.5HRAS, KRAS, NRAS
119.5HRAS, KRAS, NRAS
129.5HRAS, JAK2, RUNX2
13
Show member pathways
9.2HRAS, JAK2, KRAS, NRAS
149.2HRAS, JAK2, KRAS, NRAS
15
Show member pathways
9.2HRAS, JAK2, KRAS, NRAS
169.2HRAS, JAK2, KRAS, NRAS
179.2HRAS, JAK2, KRAS, NRAS
18
Show member pathways
9.2CBL, HRAS, JAK2, KIT
199.2JAK2, RUNX2, TLE1
209.2CSF1R, FLT3, KIT, RUNX2
219.2CBL, HRAS, JAK2, KRAS
229.2CBL, HRAS, JAK2, KRAS
239.2CSF1R, FLT3, RUNX1, RUNX2
249.1CBL, HRAS, KRAS, NRAS
25
Show member pathways
9.1CBL, HRAS, KRAS, NRAS
26
Show member pathways
9.1CBL, HRAS, KRAS, NRAS
27
Show member pathways
9.1CBL, HRAS, KRAS, NRAS
28
Show member pathways
9.1CBL, HRAS, KRAS, NRAS
299.1FLT3, HRAS, KIT, KRAS, NRAS
30
Show member pathways
9.1FLT3, HRAS, KIT, KRAS, NRAS
31
Show member pathways
8.9CBL, FLT3, HRAS, KRAS, NRAS
32
Show member pathways
8.8CSF1R, HRAS, KIT, KRAS, NRAS
338.8CBL, CSF1R, FLT3, JAK2, KIT
34
Show member pathways
8.8CBL, HRAS, KRAS, NRAS, RUNX1
358.8CBL, HRAS, JAK2, KRAS, NRAS
36
Show member pathways
8.8CBL, HRAS, JAK2, KRAS, NRAS
37
Show member pathways
8.8CBL, HRAS, JAK2, KRAS, NRAS
38
Show member pathways
8.8CBL, HRAS, JAK2, KRAS, NRAS
39
Show member pathways
8.8CBL, HRAS, JAK2, KRAS, NRAS
408.7CSF1R, CSF3, FLT3, KIT
41
Show member pathways
8.6CBL, HRAS, JAK2, KIT, KRAS, NRAS
42
Show member pathways
8.6CBL, FLT3, HRAS, JAK2, KRAS, NRAS
43
Show member pathways
8.5CSF1R, HRAS, JAK2, KIT, KRAS, NRAS
44
Show member pathways
8.4CBL, FLT3, HRAS, KIT, KRAS, NRAS
457.9CBL, CSF1R, FLT3, HRAS, KIT, KRAS
467.7CSF1R, CSF3, HRAS, JAK2, KIT, KRAS
47
Show member pathways
7.7CSF1R, CSF3, HRAS, JAK2, KIT, KRAS
48
Show member pathways
7.6CBL, CSF1R, FLT3, HRAS, KIT, KRAS
49
Show member pathways
7.5CSF1R, CSF3, FLT3, HRAS, JAK2, KIT
50
Show member pathways
7.5CSF1R, CSF3, FLT3, HRAS, JAK2, KIT

GO Terms for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

About this section

Biological processes related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 25)
idNameGO IDScoreTop Affiliating Genes
1myeloid progenitor cell differentiationGO:000231810.6FLT3, KIT
2positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.5JAK2, KIT
3stimulatory C-type lectin receptor signaling pathwayGO:000222310.1HRAS, KRAS, NRAS
4positive regulation of MAPK cascadeGO:004341010.0FLT3, HRAS, KIT
5ERBB2 signaling pathwayGO:003812810.0HRAS, KRAS, NRAS
6positive regulation of tyrosine phosphorylation of Stat3 proteinGO:004251710.0CSF1R, JAK2, KIT
7ossificationGO:00015039.9CBFB, RUNX1, RUNX2
8negative regulation of neuron apoptotic processGO:00435249.9HRAS, JAK2, KRAS
9positive regulation of MAP kinase activityGO:00434069.8FLT3, HRAS, KIT, KRAS
10positive regulation of actin cytoskeleton reorganizationGO:20002519.8CSF3, HRAS
11regulation of long-term neuronal synaptic plasticityGO:00481699.8HRAS, KRAS
12protein autophosphorylationGO:00467779.7CSF1R, FLT3, JAK2, KIT
13peptidyl-tyrosine phosphorylationGO:00181089.7CSF1R, FLT3, JAK2, KIT
14leukocyte migrationGO:00509009.7HRAS, KRAS, NRAS
15Ras protein signal transductionGO:00072659.6HRAS, KRAS, NRAS
16epidermal growth factor receptor signaling pathwayGO:00071739.6CBL, HRAS, KRAS, NRAS
17positive regulation of cell migrationGO:00303359.4CSF1R, HRAS, JAK2, KIT
18MAPK cascadeGO:00001659.4HRAS, JAK2, KIT, KRAS, NRAS
19hemopoiesisGO:00300979.3CSF1R, FLT3, KIT, RUNX1, RUNX2
20axon guidanceGO:00074119.1CSF1R, HRAS, KRAS, NRAS
21cellular response to cytokine stimulusGO:00713459.0CSF1R, CSF3, FLT3
22positive regulation of gene expressionGO:00106289.0HRAS, KIT, KRAS, RUNX2, TLE1
23positive regulation of phosphatidylinositol 3-kinase signalingGO:00140688.9CBL, CSF3, FLT3, JAK2, KIT
24cytokine-mediated signaling pathwayGO:00192218.6CSF1R, CSF3, FLT3, JAK2, KIT, KRAS
25positive regulation of cell proliferationGO:00082847.2CSF1R, CSF3, FLT3, HRAS, JAK2, KIT

Molecular functions related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cytokine bindingGO:001995510.4CSF1R, KIT
2ATP bindingGO:00055248.3ABCG2, CSF1R, FLT3, JAK2, KIT, RUNX1
3protein bindingGO:00055155.3ABCG2, CBFB, CBL, CSF1R, FLT3, HRAS

Sources for Core Binding Factor Acute Myeloid Leukemia

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet